Comment from Family Research Council

Summary: The Family Research Council, a nonprofit research and educational organization, opposes the American College of Obstetricians and Gynecologists' request to remove or reduce the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. They argue that the drug is unsafe, citing risks of sepsis and hemorrhage, and urge the FDA to instead strengthen safety protocols, including requirements for ultrasounds and blood testing.